We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Apellis (APLS) Up on Tie-up With Beam for Novel Therapies
Read MoreHide Full Article
Shares of Apellis Pharmaceuticals, Inc. (APLS - Free Report) were up 7.3% on Thursday after the company announced that it has entered into a research collaboration with Cambridge, MA-based Beam Therapeutics Inc. (BEAM - Free Report) to discover and develop novel therapies for complement-driven diseases.
In fact, the stock has rallied 18.5% so far this year compared with the industry’s increase of 1.4%.
Image Source: Zacks Investment Research
With this deal, the companies are looking to leverage Apellis’ expertise in complement, a complex biological system, along with Beam’s proprietary base-editing platform.
The companies will collaborate for an initial period of five years and work on six research programs focused on C3 and other complement targets in the eye, liver and brain.
Per the deal, Apellis will make an upfront payment of $75 million to Beam. Upon exercising the opt-in license rights for each of the programs, Beam will also be entitled to receive development/regulatory and sales-based milestones from Apellis, as well as royalties on net sales, if a product is commercialized from the above collaboration. The initial five-year deal might get extended up to two years.
While Apellis will have the rights to license each of the six programs and will take full responsibility for development, Beam may decide to equally co-develop and co-commercialize the same in the United States.
We remind investors that, in May 2021, Apellis received the FDA approval for its targeted C3 therapy, Empaveli (pegcetacoplan), as a monotherapy treatment for adult patients suffering from paroxysmal nocturnal hemoglobinuria (“PNH”), a rare blood disorder.
A marketing authorization application seeking approval for Empaveli as treatment for PNH patients is under review in Europe. A potential approval is anticipated in the second half of 2021.
Apart from PNH, Apellis is developing Empaveli for systemic administration in several indications. Empaveli is being evaluated as a monotherapy in two phase III studies, namely, DERBY and OAKS, for treating patients with geographic atrophy. Top-line data from the same is expected in the third quarter of 2021.
Repligen’s earnings estimates have been revised 18.3% and 14.7% upward for 2021 and 2022, respectively, over the past 60 days. The stock has rallied 4.3% year to date.
Trevena’s loss per share estimates have narrowed 6.4% for 2021 and 3.7% for 2022 over the past 60 days.
Zacks' Top Picks to Cash in on Artificial Intelligence
In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.
Image: Bigstock
Apellis (APLS) Up on Tie-up With Beam for Novel Therapies
Shares of Apellis Pharmaceuticals, Inc. (APLS - Free Report) were up 7.3% on Thursday after the company announced that it has entered into a research collaboration with Cambridge, MA-based Beam Therapeutics Inc. (BEAM - Free Report) to discover and develop novel therapies for complement-driven diseases.
In fact, the stock has rallied 18.5% so far this year compared with the industry’s increase of 1.4%.
With this deal, the companies are looking to leverage Apellis’ expertise in complement, a complex biological system, along with Beam’s proprietary base-editing platform.
The companies will collaborate for an initial period of five years and work on six research programs focused on C3 and other complement targets in the eye, liver and brain.
Per the deal, Apellis will make an upfront payment of $75 million to Beam. Upon exercising the opt-in license rights for each of the programs, Beam will also be entitled to receive development/regulatory and sales-based milestones from Apellis, as well as royalties on net sales, if a product is commercialized from the above collaboration. The initial five-year deal might get extended up to two years.
While Apellis will have the rights to license each of the six programs and will take full responsibility for development, Beam may decide to equally co-develop and co-commercialize the same in the United States.
We remind investors that, in May 2021, Apellis received the FDA approval for its targeted C3 therapy, Empaveli (pegcetacoplan), as a monotherapy treatment for adult patients suffering from paroxysmal nocturnal hemoglobinuria (“PNH”), a rare blood disorder.
A marketing authorization application seeking approval for Empaveli as treatment for PNH patients is under review in Europe. A potential approval is anticipated in the second half of 2021.
Apart from PNH, Apellis is developing Empaveli for systemic administration in several indications. Empaveli is being evaluated as a monotherapy in two phase III studies, namely, DERBY and OAKS, for treating patients with geographic atrophy. Top-line data from the same is expected in the third quarter of 2021.
Zacks Rank & Stocks to Consider
Apellis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Repligen Corporation (RGEN - Free Report) and Trevena, Inc. (TRVN - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Repligen’s earnings estimates have been revised 18.3% and 14.7% upward for 2021 and 2022, respectively, over the past 60 days. The stock has rallied 4.3% year to date.
Trevena’s loss per share estimates have narrowed 6.4% for 2021 and 3.7% for 2022 over the past 60 days.
Zacks' Top Picks to Cash in on Artificial Intelligence
In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.
See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>